---
title: Neural Mobilization and Capsular Stretching in Adhesive Capsulitis
nct_id: NCT07323225
overall_status: NOT_YET_RECRUITING
phase: NA
sponsor: Prince Sattam Bin Abdulaziz University
study_type: INTERVENTIONAL
primary_condition: Adhesive Capsulitis
countries: Saudi Arabia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07323225.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07323225"
ct_last_update_post_date: 2026-01-07
last_seen_at: "2026-05-12T06:48:43.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Neural Mobilization and Capsular Stretching in Adhesive Capsulitis

**Official Title:** Effectiveness of Combined Neural Mobilization Techniques and Capsular Stretching Exercises in Patients With Adhesive Capsulitis.

**NCT ID:** [NCT07323225](https://clinicaltrials.gov/study/NCT07323225)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Prince Sattam Bin Abdulaziz University
- **Conditions:** Adhesive Capsulitis
- **Start Date:** 2026-01-01
- **Completion Date:** 2026-04-10
- **CT.gov Last Update:** 2026-01-07

## Brief Summary

Restriction of glenohumeral (GH) mobility in patients with adhesive capsulitis (AC) was known owing to capsular adhesion. There is a little evidence about the involvement of neural restriction in limiting range of motion (ROM) of the GH joint in patients with AC. Objectives: The purpose of this study is to investigate the combined effect of median nerve mobilization and capsular stretching on improving shoulder external rotation, abduction and internal rotation ROM among patients with AC. Methods Thirty patients will be randomly assigned into two equal groups : Group (A) will receive median nerve mobilization and capsular stretching while Group (B) will receive only capsular stretching (anterior, posterior and anteroinferior capsular stretching). Both groups will receive passive and self-assisted exercises. All patients in both groups will be evaluated pre and post treatment for GH external rotation, abduction and internal rotation ROM.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients from both gender (male \&female) will be included if they would have second or third stage AC with their age between forty and seventy years
* experiencing pain, capsular adhesions, and a reduction of greater than fifty percentage in passive ROM of the GH joint (external rotation, abduction, and internal rotation compared to the sound side
* lasting for a minimum of three months. Patients with positive upper limb tension test-1 will be also included in this study

Exclusion Criteria:

* they would have stroke,Parkinson's diseases that interfere with shoulder muscles activity
* diabetes
* traumatic shoulder conditions
* glenohumeral osteoarthritis confirmed by x-ray
* previous surgery, and manipulation of the affected GH joint under general anesthesia
* Patients with passive elbow extension ROM
```

## Arms

- **Neural mobilization group** (EXPERIMENTAL) — neural mobilization plus capsular stretching
- **Capsular stretching group** (ACTIVE_COMPARATOR) — capsular stretching
- **Control group** (ACTIVE_COMPARATOR) — traditional execises

## Interventions

- **capsular stretching plus neural mobilization** (OTHER) — anterior, posterior and inferior capsular stretching and neural mobilization
- **anterior, inferior and posterior capsular stretching** (OTHER) — anterior, inferior and posterior glenohumeral capsular stretching
- **traditional exercises** (OTHER) — stretching exercises for anterior GH musculture plus auto passive exercises and pendulum exercises

## Primary Outcomes

- **pain intensity** _(time frame: 4 Weeks)_ — pain was assessed by VAS which has two ends. the left end indicates no pain where the right end indicates maximal pain
- **central sensitization** _(time frame: 4 weeks)_ — central sensitization will be assessed by the the arabic version of central sensitizatuion questionnaire. To understand CSI scores, the following severity categories have been established: subclinical = 0 to 29; mild = 30 to 39; moderate = 40 to 49; severe = 50 to 59; and extreme = 60 to 100

## Locations (1)

- Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.prince sattam bin abdulaziz university|al kharj||saudi arabia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07323225.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07323225*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*